MX2019003698A - Composicion que comprende al menos una sal farmaceuticamente aceptable de elafibranor soluble en medio acuoso que muestra una absorcion intestinal mejorada. - Google Patents
Composicion que comprende al menos una sal farmaceuticamente aceptable de elafibranor soluble en medio acuoso que muestra una absorcion intestinal mejorada.Info
- Publication number
- MX2019003698A MX2019003698A MX2019003698A MX2019003698A MX2019003698A MX 2019003698 A MX2019003698 A MX 2019003698A MX 2019003698 A MX2019003698 A MX 2019003698A MX 2019003698 A MX2019003698 A MX 2019003698A MX 2019003698 A MX2019003698 A MX 2019003698A
- Authority
- MX
- Mexico
- Prior art keywords
- elafibranor
- pharmaceutically acceptable
- acceptable salt
- composition
- soluble
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a una composición que comprenda como principio activo una sal farmacéuticamente aceptable de elafibranor caracterizada porque la sal farmacéuticamente aceptable de elafibranor se selecciona entre al menos una sal de colina, o de etanolamina, o de dietanolamina, o de L-lisina, o de piperazina, o de calcio, o de trometamina. La invención se refiere más especialmente al uso de sales de elafibranor destinadas a mejorar la estabilidad y la solubilidad en comparación con elafibranor en su forma de base. Estas sales permiten establecer formulaciones farmacéuticas en diferentes formas ventajosas como las inyecciones intravenosas o las formulaciones por vía enteral que muestran una absorción más rápida, menos variable y, en consecuencia, una biodisponibilidad mejor.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1659438A FR3056909B1 (fr) | 2016-09-30 | 2016-09-30 | Composition comprenant au moins un sel pharmaceutiquement acceptable d'elafibranor soluble en milieux aqueux presentant une absorption intestinale amelioree |
| PCT/EP2017/074701 WO2018060372A1 (fr) | 2016-09-30 | 2017-09-28 | Composition comprenant au moins un sel pharmaceutiquement acceptable d'elafibranor soluble en milieux aqueux presentant une absorption intestinale amelioree |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019003698A true MX2019003698A (es) | 2020-08-13 |
Family
ID=58347454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019003698A MX2019003698A (es) | 2016-09-30 | 2017-09-28 | Composicion que comprende al menos una sal farmaceuticamente aceptable de elafibranor soluble en medio acuoso que muestra una absorcion intestinal mejorada. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11185520B2 (es) |
| EP (1) | EP3518916B1 (es) |
| CN (1) | CN110234320B (es) |
| BR (1) | BR112019006435A2 (es) |
| CA (1) | CA3038726A1 (es) |
| FR (1) | FR3056909B1 (es) |
| MX (1) | MX2019003698A (es) |
| WO (1) | WO2018060372A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12053445B2 (en) | 2016-03-31 | 2024-08-06 | Genfit | Methods of treatment of cholestatic diseases |
| US20200283381A1 (en) * | 2017-11-16 | 2020-09-10 | Teva Pharmaceuticals International Gmbh | Solid state forms of elafibranor |
| EP3830070A1 (en) * | 2018-08-03 | 2021-06-09 | Genfit | Elafibranor salts |
| US11634387B2 (en) | 2019-09-26 | 2023-04-25 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| IL297436A (en) * | 2020-05-18 | 2022-12-01 | Genfit | Elafibranor for the treatment of primary sclerosing cholangitis |
| IL322676A (en) * | 2023-03-06 | 2025-10-01 | Genfit | Alfibrinor solid dosage forms |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2841900B1 (fr) | 2002-07-08 | 2007-03-02 | Genfit S A | Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations |
| US7259186B2 (en) * | 2002-12-17 | 2007-08-21 | Abbott Laboratories | Salts of fenofibric acid and pharmaceutical formulations thereof |
| CN101780049A (zh) * | 2009-01-20 | 2010-07-21 | 北京利乐生制药科技有限公司 | 一种以菲诺贝特酸及其盐为主要成份的肠溶固体制剂及其制备方法 |
| CN101863780A (zh) * | 2009-04-15 | 2010-10-20 | 北京利乐生制药科技有限公司 | 一种降血脂药物胆碱盐及其制备方法、医药用途 |
| US9221751B2 (en) | 2009-11-26 | 2015-12-29 | Genfit | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders |
| SI2504005T1 (sl) * | 2009-11-26 | 2014-04-30 | Genfit | Uporaba 1,3-difenilprop-2-en-1-on derivatov za zdravljenje ledviäśnih bolezni |
| AU2012212269B2 (en) * | 2011-01-31 | 2016-05-19 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| US20180117013A1 (en) * | 2015-03-26 | 2018-05-03 | T3D Therapeutics, Inc. | Methods of treating liver disease using indane acetic acid derivatives |
-
2016
- 2016-09-30 FR FR1659438A patent/FR3056909B1/fr not_active Expired - Fee Related
-
2017
- 2017-09-28 MX MX2019003698A patent/MX2019003698A/es unknown
- 2017-09-28 EP EP17777046.8A patent/EP3518916B1/fr active Active
- 2017-09-28 CA CA3038726A patent/CA3038726A1/fr not_active Abandoned
- 2017-09-28 BR BR112019006435A patent/BR112019006435A2/pt not_active Application Discontinuation
- 2017-09-28 WO PCT/EP2017/074701 patent/WO2018060372A1/fr not_active Ceased
- 2017-09-28 CN CN201780073672.7A patent/CN110234320B/zh not_active Expired - Fee Related
- 2017-09-28 US US16/338,219 patent/US11185520B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018060372A1 (fr) | 2018-04-05 |
| CN110234320A (zh) | 2019-09-13 |
| US20190274982A1 (en) | 2019-09-12 |
| EP3518916B1 (fr) | 2021-07-07 |
| EP3518916A1 (fr) | 2019-08-07 |
| US11185520B2 (en) | 2021-11-30 |
| BR112019006435A2 (pt) | 2019-06-25 |
| FR3056909B1 (fr) | 2019-04-19 |
| FR3056909A1 (fr) | 2018-04-06 |
| CA3038726A1 (fr) | 2018-04-05 |
| CN110234320B (zh) | 2023-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019003698A (es) | Composicion que comprende al menos una sal farmaceuticamente aceptable de elafibranor soluble en medio acuoso que muestra una absorcion intestinal mejorada. | |
| CY1122730T1 (el) | 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων | |
| MX373040B (es) | Composicion farmaceutica acuosa liquida que contiene derivados de ciclodextrina eterificada con conservador. | |
| AR081542A1 (es) | Composiciones de emulsiones farmaceuticas con bajo contenido de aceite que comprenden un progestageno | |
| EA201200096A1 (ru) | Фармацевтическая композиция ингибитора протеазы вируса гепатита c | |
| MX374497B (es) | Inhibidor del antígeno de superficie del virus de la hepatitis b. | |
| AR088382A1 (es) | Formulaciones de etanercept estabilizadas con xilitol | |
| CO2018004857A2 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
| HRP20191477T1 (hr) | Farmaceutski sastav s-ketamin hidroklorida | |
| AR077338A1 (es) | Formulacion farmaceutica. procedimiento de preparacion. disolucion para perfusion. | |
| AR108046A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| UY35684A (es) | Formulación de inhibidores de la tirosina quinasa de bazo (syk) | |
| MX2024006689A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| EA201691490A1 (ru) | Фармацевтическая композиция, содержащая бринзоламид | |
| NZ720328A (en) | Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease | |
| DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
| BR112015022758A2 (pt) | derivados de pirrolidina, composições farmacêuticas contendo os mesmos e seu uso em terapia | |
| MX385518B (es) | FORMULACIÓN QUE TIENE CARACTERÍSTICAS MEJORADAS DE LIBERACIÓN DE FÁRMACOS pH DEPENDIENTES, QUE CONTIENEN ESOMEPRAZOL O UNA DE SUS SALES FARMACÉUTICAS ACEPTABLE. | |
| AR108676A1 (es) | Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant | |
| BR112015005347A2 (pt) | composto, composição farmacêutica, e, método para tratamento ou profilaxia de infecção por hiv ou para tratamento, profilaxia, ou atraso no início de aids | |
| BR112015021480A2 (pt) | soluções de hidromorfona intratecais tendo estabi-lidade melhorada | |
| UY37550A (es) | Nueva formulación que comprende un derivado de bencimidazol | |
| MX385243B (es) | Nanoparticulas de clevidipina y composiciones farmaceuticas que las contienen. | |
| AR109168A1 (es) | Sales de derivados de 2,6-dimetilpirimidona y sus usos | |
| CL2021002107A1 (es) | Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria. |